New trends in drug procurement

A few days ago, the National Health Commission’s Department of System Reform published the "State Council’s Leading Group on Deepening the Reform of the Medical and Health System’s Implementation Opinions on Deepening the Promotion of the Experience of Sanming City, Fujian Province and Deepening the Reform of the Medical and Health System".
Compared with this, the opinions of the leading group are undoubtedly more refined
.

The opinion pointed out that the normalization and institutionalization of the national organization of centralized procurement of pharmaceutical consumables will gradually expand the scope of procurement, and strive to purchase more than 300 generic names for drugs by the end of 2022
.

At the end of the "14th Five-Year Plan" period, the number of generic names for centralized procurement of drugs by national and provincial organizations in each province will exceed 500

The author has a copy of the Medical Economics News in February this year, which has been kept since
.

The front page of the newspaper was an article written by Professor Hu Shanlian from the School of Public Health of Fudan University in Shanghai, entitled "How to Normalize and Institutionalize Drug Purchases with Volume"

This article emphasizes: "Students have proved that if sorted by purchase amount, 10% of large-variety drugs can account for 30% of the total drug cost, and 30% of drugs can account for 50% or more of the total drug cost
.

If it can be covered Optimizing the efficiency of the Pareto curve for the first 80% of the cost of drugs will effectively control the total cost of drugs

So far, the first batch of national procurement has selected 25 generic drugs in quantity, the second batch involves 33 generic and non-generic drugs, the third batch of national procurement involves 56 varieties, and the fourth batch of national procurement involves 45 varieties.

.

The total number of drugs purchased by the four batches of the country is less than 200, accounting for less than 10% of the list of basic medical insurance drugs

In late June this year, Director Gong Bo of the Medical Service Department of the Shanghai Medical Insurance Bureau made it clear in an interview with News 1+1 that the national centralized procurement of 1-5 batches of 218 chemical drugs involved a total of 220 billion yuan, accounting for all the chemicals in public medical institutions.
30% of the drug purchase amount (660 billion); the National Medical Insurance Bureau believes that the first 620 products of public medical institutions account for 80% of the total drug sales, of which 490 drugs are chemical preparations, and strive to complete the purchase in the next two years ; Other biological analogues and Chinese medicines will also be specially purchased in due course
.

Behind these seemingly boring articles and figures, the author understands that they are actually related or even influencing each other
.

Here, I remind everyone that there are several numbers worth paying attention to: 500, 218, 620, 490!

500 is the concept of the 500 directory that the author learned after obtaining the news exclusively in July 2020
.

One year so far, the 500 catalog is still divided

If the expansion is combined with 4+7, each batch will basically remain at about 43
.

Basically, it is surprisingly consistent with the state's requirement that the local annual procurement quantity should not be less than 50

And this 620 is a large-scale centralized procurement scope recognized by the official basic tone
.

490, not surprisingly, is the total amount of centralized procurement of chemical drugs purchased by the state

Well, having said all of the above, let's look at Guocai and Dicai
.

National mining: 300
.

At present, 218 has been carried out (not counting the declaration of special insulin procurement varieties).
If the rhythm of two batches a year is followed, if the insulin can be successfully completed this year, it basically means that next year, the country’s volume procurement can basically complete 300 Task
.

This basically confirms that there is a three-year window period (2020-2022) for the author's analysis of volume purchases last year, but what I did not expect is that the country is so fast and so resolute in purchasing the 300 catalog
.
Therefore, everyone who has reviewed and will be reviewed, please quickly sort out how many varieties in the 500 catalog that you have not entered the national procurement
.

Land picking: 500.
Actually there are not so many, that is, 500-300=200.
But now, the muzzle wind direction has changed significantly.
For some provinces, it is necessary to speed up and complete the task
.
There are three methods for those who have not carried out mass procurement.
One is joining and binding, such as cross-regional inter-provincial or regional inter-provincial alliances
.

The second is the province’s own development, but at present it is limited to provinces with strength or ideas (Liaoning, Zhejiang, Jiangsu, Shandong, Xinjiang, Guangdong, Jiangxi, Xinjiang, Sichuan, Chongqing, Anhui, Shanghai, etc.
)
.

The third is that for some provinces that don't have much ideas but want to complete the task, you can use the shell to complete the task-the purchase price linkage with quantity
.

Having said that, how do companies respond to and understand the situation behind the policy? Before going on the battlefield, it is not faster than someone's gun, but someone who has better preparations, stronger safeguards, more psychological preparation, and better risk prediction
.

It is recommended that pharmaceutical manufacturers do not focus on drug purchases in quantities, because from the current point of view, the top-level design department for quantity procurement is considering the formulation of plans from the perspective of medicine and equipment integration
.
Like the recent 12 provinces’ orthopedic trauma medical consumables joint procurement documents, it is worthy of serious consideration and research by all pharmaceutical companies
.

At the same time, in the recent three batches of Guangdong’s large-volume procurement drafts, there are relevant rules for the merger of different generic names, as well as the relevant policies for the procurement of Hubei Wuhan Insulin Group, the 2017 Fujian Ten Bid TCM related tender documents, and the 2021 Shanghai Bargaining Procurement Relevant Review Rules, Super Double Envelope Review Rules Appeared in the Volume Procurement Plan of Jiangxi Province, National Volume Procurement Related Policy Documents Since 2019, 2021 Hubei Proprietary Traditional Chinese Medicines Procurement Plan, etc.
, etc.
, are all worthy of enterprises.
Study the rules carefully
.

How to group, how to report the volume, the logical cause and effect between the gradual price reduction, the evolution of the price correction mechanism from 1.
8 times to 1.
5 times, the standard price and representative products appearing in the consumable procurement documents and the difference between the original drug rules and the original drug rules Point, all of this and so on
.

The special purchase of insulin must test the waters, which is destined to be cautious in the selection of this variety; the special purchase of Chinese patent medicines is also being tested, and basically it has been determined that the number of varieties is not large, but it is important to set a benchmark for the purchase of Chinese patent medicines.
The banner of one-step provincial-level procurement of Chinese patent medicines is of great significance; Guangdong inter-provincial procurement, there are some uncertain factors
.

When I sent a letter to more than a dozen provinces, the small abacus of the provinces was screaming, and there were people who couldn’t help but follow to the end; there were those who couldn’t be guilty to follow them symbolically; there were also those who followed the trend with common varieties; there were more left and right hoping to follow the boat.
Of
.

This brings about a problem that causes companies to think about it.
The adequacy of market volume directly determines the excitement of participating in Guangdong's volume procurement
.

Is the mature advantage market sufficient or insufficient? Is the small market sufficient or insufficient? Does the blank market report more than expected? If it is not grouped, the market segmentation is relatively clear
.
The killing of dominant varieties will become uncertain factors, including many factors that acquiesce in Guangdong's volume procurement policy to hospitals not reporting volume
.

The same is true for the special procurement of Chinese patent medicines.
Market changes are nothing more than substitution, combination, and expansion.
Procurement with volume is a process of competing for stock and gaining
.
Reasonable thinking tells us that we can still touch the cost of national volume purchases, and we can basically estimate a successful quotation of about 90% based on the reduction of historical batches.
There are too many uncertain factors for local volume purchases.
With so much uncertainty, it is the most important and the most important thing to look at the problem rationally.
The opinions of others are always supplementary or even serve as a reference point for less than one-tenth
.

In the face of the upcoming storm of mass procurement, I will not listen, believe, or follow blindly, think deeply, deal with it calmly, do a good job of my own affairs, study policy matters seriously, and go all out to deal with market matters.
If you think about the direction of the next step for things that conform to the law, you may not be able to achieve 90 points, and 80 points or more is fine
.
The key lies in what kind of mentality to look at and how to deal with it
.